B. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 400 South Akard Street, Dallas, Texas 75222:

1. Chalybeate Springs Corporation, Hughes Springs, Texas; to become a bank holding company by acquiring 80 percent of the voting shares of 1st National Bank of Hughes Springs, Hughes Springs, Texas.

Board of Governors of the Federal Reserve System, July 5, 1990.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 90-16121 Filed 7-10-90; 8:45 am]

BILLING CODE 6210-01-M

CS Holding; Acquisition of Company Engaged in Permissible Nonbanking Activities

July 5, 1990.

The organization listed in this notice has applied under § 225.23 (a)(2) or (f) of the Board's Regulation Y (12 CFR 225.23 (a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 2, 1990.

A. Federal Reserve Bank of New York (William L. Rutledge, Vice President) 33 Liberty Street, New York, New York 10045:

1. CS Holding, Zurich, Switzerland, and its subsidiary, *Credit Suisse,* Zurich, Switzerland; to retain Winter Partners, Inc., New York, New York, and thereby engage in data processing activities pursuant to § 225.25(b)(7) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, July 5, 1990.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 90-16122 Filed 7-10-90; 8:45 am]

BILLING CODE 6210-01-M

Omega Employee Stock Ownership Plan Trust; Change in Bank Control Notice; Acquisition of Shares of Banks or Bank Holding Companies

The notificant listed below has applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notice is available for immediate inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for the notice or to the offices of the Board of Governors. Comments must be received not later than July 25, 1990.

A. Federal Reserve Bank of Philadelphia (Thomas K. Desch, Vice President), 100 North Sixth Street, Philadelphia, Pennsylvania 19105:

1. Omega Employee Stock Ownership Plan Trust, State College, Pennsylvania; to acquire an additional 15.2 percent for a total of 24.9 percent of the voting shares of Omega Financial Corporation, State College, Pennsylvania, and thereby indirectly acquire Peoples National Bank of Central Pennsylvania, State College, Pennsylvania, and Russell National Bank, Lewistown, Pennsylvania.

Board of Governors of the Federal Reserve System, July 5, 1990.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 90-16123 Filed 7-10-90; 8:45 am]

BILLING CODE 6210-01-M

GENERAL SERVICES ADMINISTRATION

Federal Property Resources Service

[Wildlife Order 172; 7-D-MO-0607-D]

Portion, Harry S. Truman Dam and Reservoir, MO , Conveyance of Property

Pursuant to section 2 of Public Law 537, 80th Congress, approved May 19, 1948 (16 U.S.C. 667c), notice is hereby given that:

1. By transfer letter from the General Services Administration dated February 8, 1990, the property, consisting of 557.66 acres of unimproved land, known as a Portion, Harry S. Truman Dam and Reservoir, Missouri, has been transferred to the U.S. Fish and Wildlife Service, Department of the Interior.

2. The above described property was conveyed for wildlife conservation in accordance with the provisions of section 1 of said Public Law 80-537 (16 U.S.C. 667b), as amended by Public Law 92-432.

Dated: May 23, 1990.

Earl E. Jones,

Commissioner, Federal Property Resources Service.

[FR Doc. 90-16111 Filed 7-10-90; 8:45 am]

BILLING CODE 6820-96-M

[Wildlife Order 173; 7-D-KS-0430-LLL]

Tuttle Creek Lake, KS; Transfer of Property

Pursuant to section 2 of Public Law 537, 80th Congress, approved May 19, 1948 (16 U.S.C. 667c), notice is hereby given that:

1. By deed from the General Services Administration dated March 23, 1990, the property, consisting of 40.36 acres of unimproved land, known as a Tuttle Creek Lake, Kansas, has been transferred to the State of Kansas.

2. The above described property was conveyed for wildlife conservation in accordance with the provisions of section 1 of said Public Law 80-537 (16 U.S.C. 667b), as amended by Public Law 92-432.

Dated: May 23, 1990.

Earl E. Jones,

Commissioner, Federal Property Resources Service.

[FR Doc. 90-16110 Filed 7-10-90; 8:45 am]

BILLING CODE 6820-96-M

DEPARTMENT OF HEALTH AND HUMAN SERVICE

Centers for Disease Control

Advisory Committee on Childhood Lead Poisoning Prevention: Change in Meeting

This notice announce a change in the place of a previously announced meeting.

Federal Register Citation of Previous Announcement: June 28, 1990, 55 FR 26512.

Previously Announced Place: Centers for Disease Control, Center for Environmental Health and Injury Control, 4770 Buford Highway, Building 32 Conference Room, Chamblee, Georgia 30341.

Change in the Meeting: The Committee will meet at the Sheraton Century Center Hotel, Century Ballroom, 2000 Century Boulevard (off I-85 and Clairmont Road), Atlanta, Georgia 30345.

Dated: July 6, 1990.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 90-16254 Filed 7-10-90; 8:45 am]

BILLING CODE 4160-18-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 89D-0140]

Guideline for Residual Moisture Testing for Biological Products; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guideline summarizing the technical considerations and applicability of analytical methods acceptable to FDA for quantitating residual moisture in dried (e.g., lyophilized) biological products. The guideline was prepared by the Center for Biologics Evaluation and Research of FDA. Elsewhere in this issue of the Federal Register, FDA is issuing a final rule amending the biologics regulations (21 CFR 610.13(a)) to which the above guideline pertains.

ADDRESSES: Submit written requests for single copies of the guideline for residual moisture testing in dried biological products to the Congressional, International, and Consumer Affairs Branch (HFB-142), Park Bldg., rm. 158, 5600 Fishers Lane, Rockville, MD 20857, 301-443-7532. Send two self-addressed, adhesive labels to assist that office in processing your requests. Submit written comments on the guideline to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. Copies of the guidelines and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Joan C. May, Center for Biologics Evaluation and Research (HFB-740), Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, 301-496-4570.

SUPPLEMENTARY INFORMATION: In the Federal Register of June 29, 1989 (54 FR 27428), FDA announced the availability of, and invited public comment on, a draft guideline for residual moisture testing in dried (e.g., lyophilized) biological products. The draft guideline summarized the technical considerations and applicability of analytical methods acceptable to FDA for quantitating residual moisture. FDA is announcing the availability of a guideline, based on the draft guideline and revised by FDA to incorporate minor changes suggested by interested parties.

This notice of availability of a residual moisture testing guideline is announced under 21 CFR 10.90(b), which provides for use of guidelines to establish procedures of general applicability that are not legal requirements but are acceptable to FDA. Reliance upon the guidelines assures that conduct will be acceptable to FDA. Alternative procedures or standards may be considered even though they are not provided for in the guideline. Use of alternative procedures or standards may be discussed with FDA to prevent expenditure of money and effort for work that FDA may later determine to be unacceptable. Under 21 CFR 601.12, however, use of alternative procedures or standards requires that such changes be reported to and approved by FDA.

Elsewhere in this issue of the Federal Register, FDA is issuing a final rule amending the biologics regulations in § 610.13, to which the above guideline pertains. The amendment reflects the availability of alternative analytical methods, in addition to the method cited in the existing regulation, for quantitating residual moisture. This amendment permits manufacturers to select the most appropriate analytical method for residual moisture testing on a product-by-product basis. The amendment recognizes the fact that different, yet still acceptable, analytical methods may yield different residual moisture results, due to differences in methodological specificity and sensitivity. The amendment accommodates such differences in residual moisture results by allowing the analytical method and the correspondingly appropriate residual moisture limit for a given product to be specified by the manufacturer in the product license application.

Interested persons may submit written comments on the guideline to the Dockets Management Branch (address above). Such comments will be considered in determining whether further amendments to, or revisions of, the guidelines are warranted. Two copies of any comments are to be submitted, except that individuals may submit one copy.

Dated: June 20, 1990.

Ronald G. Chesemore,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 90-16117 Filed 7-10-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 89P-0222]

Liquid Eggs Deviating From the Standard of Identity; Amendment of Temporary Permit for Market Testing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that it is amending a temporary permit, issued to Crystal Foods, Inc., to market test experimental packs of liquid eggs, designated as "ultrapasteurized liquid whole eggs" and "ultrapasteurized liquid whole eggs with citric acid," to provide for package sizes larger than the designated 2.27 kilograms (kg) (5 pounds (lb)). This amendment will provide the permit holder with a broader base for the collection of data on consumer acceptance of the test product.

FOR FURTHER INFORMATION CONTACT: Joanne Travers, Center for Food Safety and Applied Nutrition (HFF-414), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-485-0106.

SUPPLEMENTARY INFORMATION: FDA issued a temporary permit under the provisions of 21 CFR 130.17 to Crystal Foods, Inc., 6465 Wayzata Blvd.,

Minneapolis, MN 55426, to market test experimental packs of liquid eggs designated as "ultrapasteurized liquid whole eggs" and "ultrapasteurized liquid whole eggs with citric acid." These products are not provided for in the U.S. standard of identity for liquid eggs in 21 CFR 160.115 because they are processed by a special procedure that involves increased heat treatment combined with aseptic processing and packing. The purpose of the special process is to (1) Render the egg product free of *Salmonella* and *Listeria monocytogenes*, (2) substantially reduce the number of spoilage bacteria in the liquid whole eggs with citric acid, (3) prevent postprocess contamination of the products, and (4) obtain a shelf-life greater than 4 weeks under refrigeration. Citric acid is added at a level of 0.15 percent to preserve color. The purpose of the temporary permit is to measure consumer acceptance of this new method of processing liquid eggs.

The agency issued the permit to facilitate market testing of a food that deviates from the requirements of the standard of identity for liquid eggs (21 CFR 160.115) promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341). Notice of issuance of the temporary permit to Crystal Foods, Inc., was published in the Federal Register of July 21, 1989 (54 FR 30612).

Crystal Foods, Inc., has requested that FDA amend its temporary permit to allow the test product to be packaged in larger aseptic bags ranging from 6.82 kg (15 lb) to 1,290 kg (2,838 lb) (tote size) aseptic bags. The company states that these changes in package size are necessary, based on preliminary acceptance of the product in its current package size and commercial feasibility, to collect additional data to complete the market test.

Accordingly, under the provisions of 21 CFR 130.17(f), FDA is amending the permit to provide marketing of the test product in 6.82 kg (15 lb) to 1,290 kg (2,838 lb) aseptic bags as well as in 1 kg (2.2 lb) and 2.27 kg (5 lb) packages. All other terms and conditions of this permit remain unchanged.

Dated: June 25, 1990

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-16178 Filed 7-10-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90N-0226]

Parke-Davis Co., et al.; Withdrawal of Approval of New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) withdraws approval of 16 new drug applications (NDA's). The action is based on the written requests of the applicants because the products are no longer marketed.

EFFECTIVE DATE: August 10, 1990.

FOR FURTHER INFORMATION CONTACT: Ron Lyles, Center for Drug Evaluation and Research, Document Management and Reporting Branch (HFD-53), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4320.

SUPPLEMENTARY INFORMATION: The holders of the NDA's listed below have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by request, waived their opportunity for a hearing.

NDA No.	Drug name	Applicant name and address
4-154	Sulfadiazine Tablets	Park-Davis, Division of Warner-Lambert Co., 201 Tabor Rd., Morris Plains, NJ 07950.
4-232	Phemerol Tincture	Do.
6-580	0.9% Ammonium Chloride and 0.9% Sodium Chloride Injection	Kendall McGraw Laboratories, Inc., 2525 McGraw Ave., Irvine, CA 92714-5895.
6-905	Norisodrine Sulfate Aerohaler	Abbott Laboratories, Pharmaceutical Products Division, Abbott Park, IL 60064.
7-530	Heparin Injection	Lederle Laboratories, Division of American Cyanamid Co., Pearl River, NY 10965.
8-545	Covicone Cream	Abbott Laboratories.
11-276	Compazine Concentrate	Smith Kline & French Labs., 1500 Spring Garden St., Philadelphia, PA 19101.
13-117	Somnafac Capsules	Cooper Vision Inc., P.O. Box 367, San German, PR 00753.
14-601	Meprobamate Tablets, 400 mg	Private Formulations, Inc., 460 Plainfield Ave., Edison, NJ 08818-1904.
16-150	Index Disposable Enema	Pharmacia Laboratories, Division of Pharmacia Inc., 800 Centennial Ave., Piscataway, NJ 08854-1327.
16-350-5%	Dextrose Injection in Plastic Container	Baxter Healthcare Corp., Route 120 & Wilson Rd., Round Lake, IL 60073.
16-352	5% Dextrose Injection Modified in Plastic Container	Do.
16-357	0.9% Sodium Chloride Injection, Modified, in Pastic Container	Do.
18-320	Tenucap 25 mg Capsules	Merrell Dow Pharmaceuticals, Inc., 2110 E. Galbraith Rd., P.O. Box 156300, Cincinnati, OH 45215-6300.
18-512	3% Sorbitol Irrigating Solution in plastic container	Baxter Healthcare Corp.
18-758	20% Travamulsion Intravenous Emulsion	Do.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director of the Center for Drug Evaluation and Research (21 CFR 5.82), approval of the NDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective August 10, 1990.

Dated: July 4, 1990.

Carl C. Peck,

Director, Center for Drug Evaluation and Research.

[FR Doc. 90-16119 Filed 7-10-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90M-0210]

Eye Technology, Inc.; Premarket Approval of Models 14760-5 and 14760-6 Ultraviolet-Absorbing Posterior Chamber Intraocular Lenses

AGENCY: Food and Drug Administration; HHS.